RBL Figure 1
Innovation Pharmaceuticals Receives Data Supporting Brilacidin’s Direct Inhibition of SARS-CoV-2, the Novel Coronavirus Responsible for COVID-19
April 01, 2020 08:21 ET | Innovation Pharmaceuticals Inc.
WAKEFIELD, Mass., April 01, 2020 (GLOBE NEWSWIRE) -- Innovation Pharmaceuticals (OTCQB:IPIX) (“the Company”), a clinical stage biopharmaceutical company, announced today it has received data...
Innovation Pharmaceuticals Brilacidin to be Researched as Possible Novel Coronavirus (COVID-19) Vaccine; Brilacidin Now Being Tested as Drug and Vaccine at Different Institutions
March 17, 2020 07:30 ET | Innovation Pharmaceuticals Inc.
WAKEFIELD, Mass., March 17, 2020 (GLOBE NEWSWIRE) -- Innovation Pharmaceuticals (OTCQB:IPIX) (“the Company”), a clinical stage biopharmaceutical company, announced today further details on the...
Innovation Pharmaceuticals Announces Testing Procedures of Brilacidin Against Coronavirus (COVID-19)
March 12, 2020 08:00 ET | Innovation Pharmaceuticals Inc.
WAKEFIELD, Mass., March 12, 2020 (GLOBE NEWSWIRE) -- Innovation Pharmaceuticals (OTCQB:IPIX) (“the Company”), a clinical stage biopharmaceutical company, announced today research procedures that one...
U.S. Regional Biocontainment Lab to Begin Testing of Brilacidin Against Coronavirus (COVID-19) Next Week
March 10, 2020 08:20 ET | Innovation Pharmaceuticals Inc.
WAKEFIELD, Mass., March 10, 2020 (GLOBE NEWSWIRE) -- Innovation Pharmaceuticals (OTCQB:IPIX) (“the Company”), a clinical stage biopharmaceutical company, is pleased to inform shareholders that...
vystar_green_Logo 2019.jpg
Vystar Contracts Med Air Solutions to White Label ViraTech Air Purification Systems And Distribute to Medical Housing Markets, Nursing Homes and Ecuador
June 10, 2019 08:30 ET | Vystar Corp
WORCESTER, Mass., June 10, 2019 (GLOBE NEWSWIRE) -- Vystar® Corp. (OTC: VYST) and Competitive Edge Services LLC DBA Med Air Solutions (MAS) have signed an agreement whereby Med Air Solutions will...